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Discovering New Drugs on the Cellular Level
Originating Technology/   
NASA Contribution 
With the Vision for Space Exploration calling for a sustained human presence in space, astro-nauts will need to grow plants, while in orbit, 
for nourishment that they will not receive from only con-
suming dehydrated foods. As a potential source of food 
for long-duration missions, space-grown plants could 
also give astronauts an important psychological boost, as 
fresh vegetables could serve as a welcomed change from 
monotonous meals consisting of reconstituted foods in 
plastic bags. Even more, these plants could likely aid in 
the recycling of air and wastewater on spacecraft.
With a helping hand from a company by the name of 
Biolog, Inc., NASA is studying the impacts of decreased 
gravity and spaceborne bacteria on the plants being grown 
for food in space.
With a helping hand from NASA, this very same com-
pany is creating powerful new cell- and bacteria-analysis 
tools for use in discovering and developing new drugs 
on Earth.
Partnership
From 1993 to 1997, Hayward, California-based Biolog 
received Phase I and II Small Business Innovation 
Research (SBIR) contracts from Kennedy Space Center 
to work with NASA in developing two technologies that 
are now in use by Biolog customers worldwide. The first 
technology, based on the company’s pre-existing assay 
kits, was a process created to monitor populations of 
microbes. Dr. Jay Garland, manager of the Life Support 
Group at Kennedy, was interested in using this process as 
a way of monitoring the health of hydroponic crops that 
would be grown in space during future manned missions 
to Mars. The second technology was an instrumented 
system that would allow automated monitoring of 
Biolog’s assay kits for NASA’s purposes. Together, these 
innovations intended to provide NASA with better means 
of growing food in space and avoiding a catastrophic crop 
failure during long-term space travel. 
Product Outcome
Biolog went on to extend the technologies it developed 
with SBIR assistance from NASA in order to bring two 
novel and important cell-testing technologies to market: 
the Phenotype MicroArray and the OmniLog System. 
Biolog’s Phenotype MicroArray technology is comple-
mentary to DNA microarrays and proteomic technolo-
gies, which allow scientists to detect changes in levels of 
genes or proteins that direct most cellular functions. By 
measuring the patterns of change in genes and proteins, 
scientists are attempting to correlate the findings with 
something important, such as a disease state. A major goal 
would be to understand the biochemical basis underlying 
a disease and gain insight into how to correct the prob-
lem. However, according to Biolog, there are typically 
hundreds to thousands of changes that are detected by 
these gene and protein analyses and it is often difficult to 
judge which ones are really significant to the cell.
“A big advantage we have with our Phenotype 
MicroArray cellular assays is that we are measuring change 
at the cellular level,” claimed Dr. Barry Bochner, Biolog 
chairman and chief scientific officer. “Proteomics and 
gene expression don’t necessarily give enough insight—
often, you don’t really know what it means to the cell. 
The data we get is at a higher level in terms of informa-
tion content and can be simpler to interpret.”
Because of this, the Phenotype MicroArray represents 
the third major technology that is needed in the genomic 
era of research and drug development, according to the 
Biolog, Inc.’s product lines have been built upon patented technology that greatly simpliﬁes testing of cells. Principal 
customers include pharmaceutical, biotech, and cosmetic laboratories, as well as laboratories testing for human, 
animal, and plant diseases.
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company. Just as DNA microarrays and proteomic sci-
ence have made it possible to assay the level of thousands 
of genes or proteins all at once, the Phenotype MicroArray 
technology makes it possible to quantitatively measure 
thousands of cellular traits (phenotypes) simultaneously, 
in both microbial and mammalian cells. Such measure-
ments can be critical in determining the effects of genetic 
changes and drug exposure on cells. 
In the field of drug discovery, the Phenotype 
MicroArray allows researchers to obtain a comprehensive 
picture of a drug’s effect on a specific cell. “People usually 
do this type of assay on cells in a rapid growth state, and 
they’re only looking at the cell under one state,” Bochner 
noted. “But a cell is always changing. With our technol-
ogy, you can take a drug and get a very information-rich 
fingerprint of its effect on the cell under a wide range of 
physiological states.”
Incubation and recording of phenotypic data gath-
ered from the Phenotype MicroArray are performed by 
the OmniLog PM System, an integrated system of cellu-
lar assays, instrumentation, and bioinformatics software. 
Just as it automatically monitored assay kits for NASA, 
the OmniLog technology monitors thousands of phe-
notypes simultaneously. Several times each hour, it cap-
tures digital images of the cell assays being studied and 
stores quantitative color change values as computer files. 
These files can be displayed in the form of kinetic graphs 
and up to 480,000 data points can be generated in a 
24-hour period. 
Another version of the OmniLog product, called 
the OmniLog ID System, can be paired with Biolog’s 
microbial-identification kits to easily and efficiently 
identify over 2,000 species of aerobic and anaerobic bac-
teria, yeasts, and fungi, virtually everything from A to Z 
(Achromobacter cholinophagum to Zygosporium mycophilum). 
The principal customers for Biolog’s Phenotype 
MicroArray and OmniLog products are laboratories 
requiring state-of-the-art capabilities in cell-based assay 
and identification products, especially pharmaceuti-
cal, biotech, cosmetics, and medical device companies; 
university and government research laboratories; labora-
tories testing for diseases of humans, animals, and plants; 
laboratories performing environmental monitoring; and 
companies or organizations involved in production or test-
ing of food and drink. 
Applications of the NASA-funded technology continue 
to expand and evolve. Biolog recently announced that the 
Phenotype MicroArray and OmniLog products have been 
installed at the Lawrence Livermore National Laboratory, 
in Livermore, California, where genomics researchers are 
using the technology to understand and characterize phe-
notypes of bacteria strains that are considered potential 
bioterrorism agents. Other important government labora-
tories such as the U.S. Food and Drug Administration and 
the U.S. Department of Agriculture are also employing 
the technologies to better understand foodborne patho-
genic bacteria and the spread of epidemics. 
Additionally, Biolog is sharing its innovations with the 
Nara Institute of Science and Technology, in Japan, in 
an effort to broaden what is known about the functions 
of genes in the important bacterium E. coli. According to 
Tim Mullane, Biolog president and chief executive officer, 
“E. coli is one of the most studied model cell lines in the 
world, and despite the early sequencing of this organism’s 
genome, many of its 4,000 genes have no known func-
tion. Even where function is known, this information is 
often incomplete.”
Next on the list for Biolog is to broaden the technolo-
gies for use with human cells. The company will soon 
be releasing Phenotype MicroArrays that can assess the 
energy metabolism pathways in cells from different organs 
and tissues. This should aid studies in diabetes, obesity, 
and cancer.  ❖
Phenotype MicroArray™ is a trademark of Biolog, Inc.  
OmniLog® is a registered trademark of Biolog, Inc.
A Biolog, Inc., laboratory technician performs cellular tests 
using Phenotype MicroArray  assays and the OmniLog 
System. The technology is capable of monitoring thousands 
of phenotypes simultaneously. 
